418 related articles for article (PubMed ID: 20924616)
21. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?
Ekpanyapong S; Reddy KR
Clin Liver Dis; 2020 Aug; 24(3):317-333. PubMed ID: 32620274
[TBL] [Abstract][Full Text] [Related]
23. [Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab].
Mimura N; Kojima H; Tsujimura H; Ise M; Sakai C; Fukai K; Yokosuka O; Kumagai K
Rinsho Ketsueki; 2010 Mar; 51(3):213-5. PubMed ID: 20379117
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Tachi Y; Ishikawa T; Katano Y; Yoshioka K; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol; 2016 Nov; 51(11):1081-1089. PubMed ID: 26943169
[TBL] [Abstract][Full Text] [Related]
25. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
[TBL] [Abstract][Full Text] [Related]
26. [Reactivation of chronic hepatitis B].
Šperl J
Vnitr Lek; 2013 Jul; 59(7):591-6. PubMed ID: 23909265
[TBL] [Abstract][Full Text] [Related]
27. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
29. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature?
Yenilmez E; Cetinkaya RA
Infez Med; 2019 Sep; 27(3):299-307. PubMed ID: 31545774
[TBL] [Abstract][Full Text] [Related]
30. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma.
Loglio A; Viganò M; Grossi G; Labanca S; Goldaniga M; Pompa A; Farina L; Rumi M; Corradini P; Facchetti F; Lunghi G; Baldini L; Lampertico P
Dig Liver Dis; 2019 Mar; 51(3):419-424. PubMed ID: 30316785
[TBL] [Abstract][Full Text] [Related]
31. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Viganò M; Mangia G; Lampertico P
Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
[TBL] [Abstract][Full Text] [Related]
32. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy?
Papamichalis P; Alexiou A; Boulbou M; Dalekos GN; Rigopoulou EI
Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):84-93. PubMed ID: 21920838
[TBL] [Abstract][Full Text] [Related]
33. Prospective study of hepatitis B virus reactivation in patients with hematological malignancies.
Pompili M; Basso M; Hohaus S; Bosco G; Nosotti L; D'Andrea M; Fenu S; Grieco A; Laurenti L; Mirisola C; Pagano L; Rapaccini GL; Sica S; Storti S; Landolfi R
Ann Hepatol; 2015; 14(2):168-74. PubMed ID: 25671825
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study.
Kusumoto S; Tanaka Y; Suzuki R; Watanabe T; Nakata M; Takasaki H; Fukushima N; Fukushima T; Moriuchi Y; Itoh K; Nosaka K; Choi I; Sawa M; Okamoto R; Tsujimura H; Uchida T; Suzuki S; Okamoto M; Takahashi T; Sugiura I; Onishi Y; Kohri M; Yoshida S; Sakai R; Kojima M; Takahashi H; Tomita A; Maruyama D; Atsuta Y; Tanaka E; Suzuki T; Kinoshita T; Ogura M; Mizokami M; Ueda R
Clin Infect Dis; 2015 Sep; 61(5):719-29. PubMed ID: 25935551
[TBL] [Abstract][Full Text] [Related]
35. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.
Hsu C; Tsou HH; Lin SJ; Wang MC; Yao M; Hwang WL; Kao WY; Chiu CF; Lin SF; Lin J; Chang CS; Tien HF; Liu TW; Chen PJ; Cheng AL;
Hepatology; 2014 Jun; 59(6):2092-100. PubMed ID: 24002804
[TBL] [Abstract][Full Text] [Related]
38. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb.
Sarrecchia C; Cappelli A; Aiello P
J Infect Chemother; 2005 Aug; 11(4):189-91. PubMed ID: 16133710
[TBL] [Abstract][Full Text] [Related]
39. [Hepatitis B virus reactivation in rituximab-treated patients: incidence and risk factors].
Gutiérrez García ML; Alonso Lopez S; Martín Rios MD; Sanmartin Fenollera P; Agudo Fernandez S; Fernández Rodriguez CM
Gastroenterol Hepatol; 2015 Jan; 38(1):1-6. PubMed ID: 25205080
[TBL] [Abstract][Full Text] [Related]
40. [Fulminant hepatic failure with hepatitis B virus reactivation after rituximab treatment in a patient with resolved hepatitis B].
Chung SM; Sohn JH; Kim TY; Yoo KD; Ahn YW; Bae JH; Jeon YC; Choi JH
Korean J Gastroenterol; 2010 Apr; 55(4):266-9. PubMed ID: 20389182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
